Résistance clinique au STI571 : implication du gène bcr-abl lui-même ?

François-Xavier Mahon

doi:doi:10.1051/medsci/200117111192

Accès gratuit

Numéro		Med Sci (Paris) Volume 17, Numéro 11, Novembre 2001


Page(s)		1192 - 1193
Section		Nouvelles
DOI		http://dx.doi.org/10.1051/medsci/200117111192
Publié en ligne		15 November 2001

Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340 : 1330–40.
Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344 : 1031–7.
Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344 : 1038–42.
Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL Gene Mutation or Amplification. Science 2001; 293 : 876–80.
Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000; 95 : 3498–505.
le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95 : 1758–66.
Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571 : diverse mechanisms of resistance. Blood 2000; 96 : 1070–9.
Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289 : 1938–42.
Hochhaus A, Krei S, Corbin A, et al. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293 : 2163a.
Barthe C, Cony-Makhoul P, Melo JV, Reiffers J, Mahon FX. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293 : 2163a.

[1] Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340 : 1330–40.

[2] Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344 : 1031–7.

[3] Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344 : 1038–42.

[4] Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL Gene Mutation or Amplification. Science 2001; 293 : 876–80.

[5] Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000; 95 : 3498–505.

[6] le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95 : 1758–66.

[7] Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571 : diverse mechanisms of resistance. Blood 2000; 96 : 1070–9.

[8] Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289 : 1938–42.

[9] Hochhaus A, Krei S, Corbin A, et al. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293 : 2163a.

[10] Barthe C, Cony-Makhoul P, Melo JV, Reiffers J, Mahon FX. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293 : 2163a.

Prix Nobel 2012